会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins
    • Herstellung von 3-biclyclipyridinium-methyl Cephalosporinen。
    • EP0138552A2
    • 1985-04-24
    • EP84306866.9
    • 1984-10-09
    • ELI LILLY AND COMPANY
    • Katner, Allen Samuel
    • C07D501/46
    • C07D471/04C07D513/04
    • Cephalosporin compounds substituted in the 7-position by a 2-(5- or 6-membered heterocyclic)-2-oximinoacetyiamino group and of the formula
      in which R is hydrogen, formyl, a-aminoadipoyl, protected a-aminoadipoyl, or an acyl group of the formula
      in which R' is a 5- or 6-membered heterocyclic ring of the for mulae


      R" is hydrogen, C 1 -C 4 alkyl, a carboxy-substituted alkyl or carboxy-substituted cycloalkyl group of the formula:

      in which n is 0-3; a and b when taken separately are, independently, hydrogen or C 1 -C 3 alkyl, and when taken together with the carbon to which they are bonded form a C 3 -C 7 carbocyclic ring; R"' is hydrogen, C 1 -C 4 alkoxy, amino, or OR°, in which R° is indanyl, phthalidyl, or an acyloxymethyl group of the formula -CH 2 -O-C(O)-R 2 in wich R 2 is C 1 -C 4 alkyl or phenyl; or COOR° is a protected carboxy group; or R" is an N-substituted carbamoyl group of the formula
      in which R"" is C 1 -C 4 alkyl, phenyl or C 1 -C 3 alkyl substituted by phenyl;

      Y and m, independently, are integers equal to 0,1,2 or 3, provided that y plus m equals 3;
      R 1 is hydrogen, C 1 -C 4 alkyl, phenyl, thienyl, amino or C 1 -C 4 alkanoylamino;
      X is O, S or N-R 2 , where R 2 is hydrogen or C 1 -C 4 alkyl; or a pharmaceutically-acceptable salt or biologically-cleavable ester thereof.
    • 通过2-(5-或6-元杂环)-2-肟基乙酰基氨基和式CHEM的7-位取代的头孢菌素化合物,其中R是氢,甲酰基,α-氨基己二酰基,保护的α-氨基己二酰基, 或式CHEM的酰基,其中R min是式CHEM> R sec的5-或6-元杂环是氢,C1-C4烷基,羧基取代的烷基或羧基取代的环烷基 组式为:其中n为0-3的; a和b分别独立地为氢或C 1 -C 3烷基,并且当与它们所键合的碳一起形成C 3 -C 7碳环时; R“是氢,C 1 -C 4烷氧基,氨基或OR 0,其中R 0是2,3-二氢化茚基,邻苯二酰基或式-CH 2 -O(O)-R 2的酰氧基甲基,其中R 2是 C 1 -C 4烷基或苯基; 或COOR <0>是被保护的羧基; 或R sec为式 - @ -NHR sec sec的N-取代氨基甲酰基,其中R sec sec为C 1 -C 4烷基,苯基或被苯基取代的C 1 -C 3烷基; Y和m独立地是等于0,1,2或3的整数,条件是y加m等于3; R 1是氢,C 1 -C 4烷基,苯基,噻吩基,氨基或C 1 -C 4烷酰基氨基; X是O,S或N-R 2,其中R 2是氢或C 1 -C 4烷基; 或其药学上可接受的盐或生物可裂解的酯。
    • 3. 发明公开
    • O-substituted oximino cephalosporins
    • O-取代的肟基头孢菌素
    • EP0233780A3
    • 1989-02-01
    • EP87301364.3
    • 1987-02-17
    • ELI LILLY AND COMPANY
    • Katner, Allen Samuel
    • C07D501/36A61K31/545
    • C07D501/36
    • O-Substituted oximinocephalosporins represented by the formula
      wherein R is a 5-membered or 6-membered heterocycle, preferably amino-substituted, e.g., 2-aminothiazol-4-yl, R 1 is an arylalkyl, aryloxyalkyl, or arylthioalkyl group, especially substituted benzyl; R 2 is a 1,2,4-triazin-3-yl thio group; and M is a salt or a biologically labile ester group; are potent antibacterial agents. Also provided are antibiotic formulations of said compounds and a method for treating infectious diseases in man or other animals comprising the administration of said compounds.
    • 由下式代表的O-取代的肟基头孢菌素:其中R是5元或6元杂环,优选氨基取代的,例如2-氨基噻唑-4-基,R1是芳基烷基,芳氧基烷基或芳硫基烷基,特别是取代的苄基 ; R2是1,2,4-三嗪-3-基硫基; M是盐或生物不稳定的酯基; 是有效的抗菌剂。 还提供了所述化合物的抗生素制剂以及用于治疗人或其他动物中的感染性疾病的方法,其包括施用所述化合物。
    • 8. 发明公开
    • Bis-tetrazolemethyl substituted beta-lactam antibiotics, their preparation and pharmaceutical formulations containing them
    • 双 - 取代的tetrazolmethylβ-内酰胺抗生素,其制备方法和含有它们的药物制剂。
    • EP0048165A1
    • 1982-03-24
    • EP81304238.9
    • 1981-09-16
    • ELI LILLY AND COMPANY
    • Katner, Allen Samuel
    • C07D498/04A61K31/535
    • C07D257/04C07D505/00
    • Broad spectrum β-lactam antibiotics are described. They are represented by the formula
      wherein R is hydrogen or an acyl group of the formula
      wherein R° is an aryl or aralkyl group of the formula
      wherein R' is phenyl or phenyl substituted by halogen, hydroxy amino, acetamido, C,-C 4 alkyl, C 1 -C 4 alkoxy, cyano, carboxy, carboxamido, carboxymethyl, C,-C 4 alkoxycarbony-Imethyl, hydroxymethyl, or aminomethyl; or R' is a di- or tri-substituted phenyl group of the formula
      wherein each of a, a', and a" are independently hydrogen, halogen, hydroxy, C 1 -C 4 alkyl or C 1 -C 4 alkoxy; and
      or R° is an aryloxymethyl or arylthiomethyl group of the formula
      wherein R' has the same meanings as defined above. and z is O or S; or R° is a heterocyclic methyl group of the formula
      wherein R 2 is thienyl, furyl, 1H-tetrazol-1-yl, 1H-tetrazol-5-yl,
      wherein each b is hydrogen, amino, protected-amino, C 1 -C 3 alkyl or phenyl; or R° is a group of the formula
      wherein R 3 is R' as defined above and in addition 1,4-cyclohexadienyl, thienyl or furyl, and Q is hydroxy, carboxy, sulfo, or amino; or R° is an oximino substituted group represented by the formula
      wherein R 4 is R' as defined above and in addition thienyl, furyl, or
      wherein b has the same meanings as defined above and R 5 is hydrogen, or C 1 -C 4 alkyl; or R° is a group of the formula
      wherein R 3 is as defined above and R 6 is phenyl substituted by 1-3 hydroxy groups or pyridyl substituted with from 1-3 hydroxy groups; or R 6 is a group of the formula
      wherein R' is C 1 -C 4 alkylamino, phenyl, chlorophenyl, furyl, styrryl, chlorostyrryl, or nitrostyrryl; or R 6 is a group of the formula
      wherein n' is 1 or 2 and m is 2 or 3 with the limitation that when n' is 2, m is 2; and R 8 is hydrogen, C 1 -C 3 alkyl, C 2 -C 4 alkanoyl, or C 1 -C 3 alkylsulfonyl; R, is hydrogen or a carboxy protecting group; R 2 is hydrogen or methoxy; R 3 is a bis-tetrazolemethyl group of the formula
      wherein R 4 is hydrogen or C 1 -C 3 alkyl; and when R, is hydrogen, the pharmaceutically acceptable salts thereof.
      The compounds are obtained by reacting a 7-acylamino-3-halomethyl-1-oxa-β-lactam ester with the desired 1- or 2-tetrazolemethyl substituted 1H or 2H tetrazole-5-thiol, or alternatively by reacting a 7-amino-3-halomethyl-1-oxa-b-lactam ester with the bis-tetrazole thiol and then N-acylating with the desired carboxylic acid.